Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Oxytocin

Pitocin, Syntocinon

Quick Stats
Studies 93
Trials 100
Withdrawn PHASE4 INTERVENTIONAL NCT02410655

An Evidence Based Protocol for Oxytocin Administration in Vaginal Delivery

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The purpose of this study will be to evaluate a standardized, evidence-based protocol versus a conventional approach for the dosing of oxytocin in vaginal delivery.

Detailed Description

A traditional practice in many US hospitals includes use of 10-40 IU of Oxytocin mixed in various volumes of crystalloid administered at an unspecified and uncontrolled rate (quite often off the pump) in order to restore uterine tone and minimize routine blood loss in the third stage of labor. Many practitioners question high dose oxytocin regimens, timing and duration of Oxytocin administration for postpartum hemorrhage prophylaxis. Given the lack of a universally accepted, evidence based protocol, this study aims at comparing the efficacy of a traditional approach of administration of Oxytocin with an evidence-based designed algorithm.

Interventions

Name: Oxytocin
Type: DRUG
Description: 500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
Name: Oxytocin
Type: DRUG
Description: A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.

Primary Outcomes

Measure: Estimated blood loss
TimeFrame: 24 hours postpartum
Description:

Trial Information

NCT ID

NCT02410655

Status

Withdrawn

Study Type

INTERVENTIONAL

Phases

PHASE4

Sponsor

NYU Langone Health

Last Updated

December 15, 2025